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Abstract 
CRLX101 is a nanopharmaceutical consisting of cyclodextrin-based polymer 
molecule and camptothecin. The CRLX101 nanoparticle is designed to concentrate and 
slowly release camptothecin in tumors over an extended period of time. Tumor biopsy 
and blood samples collected from patients with advanced solid malignancies before and 
after CRLX101 treatment are subjected to immunohistochemistry and 
pharmacogenomics. The expression of Topoisomerase-1, Ki-67, CaIX, CD31 and VEGF 
decreased after CRLX101 treatment. The expressions of these proteins are inversely 
proportional with survival duration of the patients. The Drug Metabolism Enzymes and 
Transporters (DMET) array shows an allele frequency in patients similar to global 
populations with none of the SNPs associated with toxicity. The results suggest that the 
observed lower toxicity is not likely be due to different genotypes in SNPs. CRLX101 
demonstrates a promising anti-tumor activity in heavily pre-treated or treatment-
refractory solid tumor malignancies presumably by inhibition of proliferation and 
angiogenesis correlating with tumor growth inhibition. 
 
Key Words: Camptothecin, Nanoparticle, Polymer conjugate, Topoisomerase 1, HIF-1, 
Immunohistochemistry, Solid tumor 
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Background 
Cancer represents a broad group of various diseases, all involving unregulated 
and progressive cell growth. Collectively they account for approximately 13% of all 
deaths each year worldwide.1  
Camptothecin (CPT), an alkaloid extract from plants known as Camptotheca 
acuminata, exhibits an anti-cancer activity against several types of cancer cells and 
animal tumor models due, at least in part, to the inhibition of DNA topoisomerase I  
(Topo-1) and resulting cell death.
2-4
 Topo-1 remains a highly attractive drug target 
because it is essential for basic cellular processes including DNA replication, 
recombination and transcription. It is particularly up-regulated in rapidly dividing tumor 
cells.
5
  CPT inhibits the resealing of single-strand DNA breaks mediated by Topo-1.  
CPT is not used clinically because of its poor solubility and high systemic toxicity. In 
particular at physiologic pH, the active lactone ring of CPT hydrolyzes to yield the 
inactive carboxylate form that strongly binds to serum albumin, resulting in further 
driving the reaction towards the inactive form.
3
  Numerous methods and modifications 
have been employed to enhance the pharmacokinetics and pharmacodynamics of this 
compound.  For example, irinotecan and topotecan belong in the category of small 
molecule analogs of CPT that overcome some of the limitations of the parent drug 
demonstrated good antitumor activity, but their use remains limited by dose-limiting 
toxicities.
6
 
CRLX101 (formerly known as IT-101) is a nanoparticulate conjugate of 20(S)-
camptothecin (CPT) and a cyclodextrin-based polymer.
7
  In CRLX101, CPT is linked 
covalently through a glycine linker to the linear copolymer CDP, which in turn consists 
of alternating subunits of beta-cyclodextrin and polyethylene glycol (PEG).
7
 Conjugation 
of CPT to CDP increases the aqueous solubility of active CPT by three orders of 
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magnitude over native CPT and prevents inactivation through spontaneous lactone ring 
opening at physiologic pH. CRLX101 is preferentially accumulated in tumors due to 
leaky vasculature known as enhanced permeability and retention (EPR) effect, and slowly 
released inside tumor cells as the linkage is hydrolyzed, thereby reducing systemic 
exposure and the subsequent toxic side effects.
8,9
 Preclinical studies have shown that 
sustained release of active CPT from CRLX101 nanoparticles results in extended Topo-1 
and HIF-1α inhibition, thus increasing antitumor efficacy, as compared to standard 
dosing for irinotecan or topotecan.
8,10-14
 Results from several studies have shown 
presence of CRLX101 as intact nanoparticles in tumor sections from both animals and 
patients.
11,13,15,16
  
Human cancers are characterized by intratumoral hypoxia that results from 
deregulated cell proliferation. Physiological responses triggered by hypoxia affect all 
critical aspects of cancer progression, including immortalization, transformation, 
differentiation, genetic stability, angiogenesis, invasion, metastasis, treatment outcome 
and resistance to therapy.
17
  Expression of carbonic anhydrase IX (CaIX), a member of 
the carbonic anhydrase family that catalyzes the reversible hydration of carbon dioxide to 
carbonic acid, is directly driven by hypoxia inducible factor-1 (HIF-1).18 This gene 
product is expressed in many types of human cancers and is usually absent in their 
normal counterparts and is linked with poor prognosis in several tumor types.
18,19
  
Camptothecin and its analogs have been reported to function by not only inhibiting HIF-
1α transcriptional activity but also protein accumulation.20  HIF-1α is known to up-
regulate genes involved in a variety of processes, including angiogenesis.
19
  Vascular 
endothelial growth factor (VEGF) and cluster of differentiation 31 (CD31) have been 
examined widely as biomarkers for angiogenesis and are shown to correlate with stage, 
grade and prognosis of patients.
21,22
 A significant decrease in expressions of Ki-67, CaIX, 
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VEGF, and CD31 proteins in CRLX101 treated tumors was also observed in mice by 
immunohistochemistry (IHC) indicating an inhibition of proliferation, HIF-1 and 
angiogenesis.
11
   
Another challenge of the present day clinical research is to assess the least toxic 
and most effective therapy for a specific patient because of the genetic variations 
encoding for metabolizing enzymes and drug transporters, which have been demonstrated 
to affect interindividual drug responses by alteration of absorption, distribution, 
metabolism and elimination (ADME).
23
 The Affymetrix Drug Metabolism Enzymes and 
Transporters (DMET) microarray is the first assay enabling the simultaneous genotyping 
of a large number of known markers (1,936 markers in 225 genes) in drug ADME. 
CRLX101 is currently under investigation in several human trials (Clinical 
Trials. Gov Identifier: NCT01380769, NCT01652079, NCT01625936 and 
NCT01612546). We report here pharmacodynamic and pharmacogenomic responses of 
CRLX101 in patient samples enrolled in the phase1/2a clinical trial. We further 
investigated whether CRLX101 may demonstrate a different DMET profile in 
comparison to historical controls. 
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Methods 
Materials 
CRLX101 was obtained from Cerulean Pharma Inc. (Cambridge, MA). 
Antibodies against different proteins were purchased from Cell Marque (Rocklin, CA), 
Novus Biologicals (Littleton, CO), R&D Systems Inc. (Minneapolis, MN) or Spring 
Biosciences (Pleasanton, CA). PAXgene tubes were purchased from Becton, Dickinson 
(Franklin Lake, NJ).  Quantitative RT-PCR was performed using kits from Qiagen 
(Valencia, CA) and life Technologies (Carlsbad, CA). DMET array was purchased from 
Affymetrix (Santa Clara, CA). Human Cytokine Thirty-Plex Antibody Bead Kit was 
purchased from Invitrogen (Carlsbad, CA).  All other reagents were obtained from Fisher 
Scientific (Pittsburgh, PA).  
Patient selection and study design 
Patients included in the study were ≥ 18 years old with histologically or 
cytologically confirmed metastatic or unresectable solid tumor malignancies refractory to 
standard curative therapy. Additional eligibility requirements were as described in Weiss 
et al.
16
 This trial was conducted at City of Hope Comprehensive Cancer Center with the 
approval of the Clinical Protocol Review and Monitoring Committee and the Institutional 
Review Board. This was an open label, single arm, dose escalation phase 1/2a study of 
CRLX101 (2a being an amended protocol after determination of maximum tolerated dose 
(MTD) with additional patient enrollment in MTD expansion cohort). Intravenous 
CRLX101 (6,12,15 or 18 mg/m
2
) was infused over a 60-minute period on days 1, 8, and 
15 of each 28-day cycle (weekly schedule) in the early part of the phase 1 trial and 
subsequently, on days 1 and 15 of each 28-day cycle (bi-weekly schedule). CRLX101 
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treatment continued until disease progression (determined by Response Evaluation 
Criteria in Solid Tumors [RECIST] version 1.1), patient withdrawal, or excessive 
toxicity.
16
  Patient tumor samples were collected on 2-3 days prior to CRLX101 treatment 
cycle 1(pre-treatment) while another biopsy sample was collected from one patient 3 days 
after day 8 infusion of 2
nd
 cycle post CRLX101 treatment (post-treatment).  Blood 
samples were collected on day 1 of treatment prior to the initial dose and on day 8 and 15 
post CRLX101 treatment.  
Tissue preparation and immunohistochemical staining 
The immunohistochemical assays were performed using a Dako Autostainer Plus 
(Dako Colorado Inc., CO) with fresh sections of tumor biopsy tissue removed before 
and/or after the treatment as described in .
11
 Primary rabbit monoclonal Topo-1 (Abcam, 
MA),  rabbit Ki-67 (Novus Biologicals, CO), goat CaIX (R&D Systems Inc., MN), rabbit 
polyclonal VEGF (Spring Biosciences, CA) or mouse monoclonal CD31 antibody (Cell 
Marque, CA) was applied for 1 – 2 hours at room temperature (20–25°C) at a final 
concentration of 1:100 (Topo-1 and Ki-67), 1:50 (CaIX), 1:500 (VEGF) or 1:75 (CD31). 
Antigen detection was accomplished using the vectastain elite ABC goat HRP kit (Vector 
labs, CA). The sections were counterstained with Meyer's hematoxylin and each run also 
included phosphate buffered saline (PBS) replacing the primary antibody for the negative 
controls, whereas samples known to express Topo-1, Ki-67, CaIX, VEGF, or CD31 
served as positive controls. Photomicrographs were taken on a Nikon microscope 
equipped with a CCD camera (QImaging, Canada). Expression of proteins was quantified 
using a visual grading (0-no staining to 3-maximum staining) system on the basis of the 
extent of staining intensity (e.g., integrated optical density), and/or percentage of stained 
cells (e.g., total area or percentage of cells positive) for each image. 
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RNA extraction and quantitative reverse transcription-PCR (RT-PCR)  
Peripheral blood was drawn in PAXgene tubes and total cellular RNA was 
isolated from whole blood using the PAXgene Blood RNA kit (Qiagen, CA). On-column 
DNaseI digestion was performed during RNA purification to remove Genomic DNA 
contamination. The RNA concentration and A260:A280 ratio was measured using a 
Nanodrop spectrophotometer (NanoDrop Technologies Inc., DE). Subsequent cDNA 
synthesis was carried out with Invitrogen SuperScript III reagents, with 2 μg total RNA + 
5 ng/μL random hexamer primers followed by qRT-PCR in the ABI Prism Sequence 
Detection System (Applied Biosystems, CA). Reactions were run for 40 cycles of 95°C 
and 60°C alternation, for 15 and 30 seconds, respectively. Relative mRNA expression 
levels were calculated using the ΔCT method against -actin. The primer pair used is as 
follows: 
Topo-1 Forward: 5’-TGC AAA AAT AAA GAA GGA GAA GGA A - 3’ 
Topo-1 Reverse: 5’-CTC TTT AGG AAC AAA ATA GCC AT – 3’ 
 
Exploratory Biomarker Analyses: 
Plasma samples were analyzed using a Human Cytokine Thirty-Plex Antibody 
Bead Kit (Invitrogen, CA) as per the manufacturer’s protocol using the Luminex 100 
Flexmap 3D instrument (Luminex, TX) in the Clinical Immunobiology Correlative 
Studies Core Laboratory at Beckman Research Institute, City of Hope.  Briefly, the blood 
was collected in endotoxin free tubes and centrifuged at 1000xg for 10 minutes.  The 
ELISA assay was performed using plasma diluted with assay diluents and run along with 
the standards provided in the kit.  Cytokine concentrations were calculated using Bio-
Plex Manager 5.0 software with a 5-parameter curve-fitting algorithm applied to standard 
curve calculations of duplicate samples. 
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DMET array:  
Genomic DNA from blood samples collected in PAXgene tubes was extracted 
using standard phenol/chloroform/isoamyl alcohol method from patients before and after 
CRLX101 treatment. Amplification, labeling and hybridization to DMET arrays were 
performed following Affymetrix’s default protocol. Hybridized DMET arrays were 
washed and stained in the fluidic stations and scanned with the GeneChip® Scanner 3000 
7G. Genotyping call rate and concordance comparisons were analyzed using the DMET 
Console (version 1.2) software. Fixed Genotype Boundaries was used as the algorithm 
for all genotyping configurations. Samples with QC call rate less than 90% were 
excluded.  
Allele frequencies of variants on DMET array in the general population were 
obtained from Affymetrix web site, which included individuals represented from 
different regions of the world. The allele frequencies of these variants among the 14 
patients were then compared to those among the global population. Fisher’s exact test 
was used to identify the variants showing different allele frequency patterns from the 
population, with nominal p value cutoff < 0.01. 
 
Statistical Analysis:  
Graph Pad Prism 6.0 was used for statistical analysis and figure drawing. Group 
comparisons were performed using Student’s t-test or two-way ANOVA and 
mean±standard error of the mean were used to present continuous variables. A p-value 
<0.05 was considered statistically significant. Kaplan–Meier analysis was applied to 
overall survival analysis. The Pearson’s correlation coefficient analyzed the association 
between quantitative variables.  
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Results 
Clinical characteristics and administered dosage of CRLX101 in patients 
included in study are summarized in Table S1. 
 
CRLX101 inhibits topoisomerase expression 
 
  
We checked the expression level of Topo-1 in pre- and post- CRLX101-treated 
skin biopsy samples from a triple negative breast cancer patient. The pre-treatment 
biopsy sample was collected 3 days prior to the start of first cycle while the post-
treatment sample was collected 3 days after the day 15 infusion of cycle 2 of CRLX101 
(5 infusions of CRLX101). Figure 1A (i) shows a strong nuclear expression of the 
enzyme in a majority of cells. This expression was inhibited in the post-CRLX101 treated 
tumor section Figure 1A (ii).  Due to the difficulties of obtaining biopsy samples to 
measure the activity or expression of Topo-1 or various other genes in pre- and post-
CRLX101 treatment group, we measure the mRNA expression levels in blood samples. 
The patients were divided based on Topo-1 expression level and were assigned a score of 
0 (expression at day 8 less than expression at day 0) or 1 (expression at day 8 higher than 
day 0). Our results showed a pattern of decreased Topo-1 expression associated with 
longer survival duration (average survival duration fivefold in group with score of 1 
compared to score 0 group) at day 8 post-CRLX101 treatment (Figure 1B). This did not 
reach statistical significance possibly due to the small number of samples (p=0.07).  In 
order to see if there is any correlation between the survival time of these patients and pre- 
and post- CRLX101 treatment expression of Topo-1, we divided the total number of 
patients in two groups based on their survival duration. The mean survival time in group 
1 (≤ 6months, n=16) was 3.75±0.43 and group 2 (> 6 Months, n=9) was 19.33±4.23 
months. The survival duration was significantly different between the two groups 
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(p<0.005).   The pre-treatment samples showed a significantly higher expression of Topo-
1 expression in group 1 as compared to group 2 (p<0.05, Figure 1C). The expression of 
Topo-1 showed an insignificant increase at day 8 before it came down at day 15 in group 
1 patient samples while group 2 samples showed a decrease in the expression at day 8 as 
well as 15 after CRLX101 treatment (Figure 1D). These results coincide with an earlier 
report in which the immunohistochemical (IHC) staining in the nucleus of ovarian cancer 
cells isolated from ascites fluid two days following treatment of CRLX101 showed a 
30% decrease in Topo-1 expression compared to pre-treatment levels and unwinding 
activity in tumor cells that was lower on day 2 following treatment compared with 
activity prior to treatment or on day 25 following treatment.
16
    
 
CRLX101 inhibits tumor cell proliferation and angiogenesis 
 
In an attempt to understand the effect of CRLX101 in pre- and post-treatment 
samples, the tumor sections were also processed for immunohistochemical expression of 
Ki-67, CaIX, VEGF and CD31. Ki-67 antigen is the prototypical cell cycle–related 
nuclear protein expressed by proliferating cells in all phases of the active cell cycle and 
absent in resting cells and is routinely used as a marker for proliferating cells. Cells in the 
Ki-67–immunostained section obtained from pre-treated tumor showed intense brown 
staining in the nuclear region. Representative photomicrographs of Ki-67 antigen–stained 
sections from pre and post-CRLX101 treated, tumors are shown in Figure 2A&B (i). The 
IHC reveals a significant decrease in Ki-67 staining in the post CRLX101 treated section 
as compared to pretreated tumor.  
   CaIX, which is associated with dysplasia and malignant tumors showed a 
higher expression of (100% cells positive for CaIX) in the pretreated section Figure 2A 
(ii) as compared to the CRLX101 post-treatment tumor section Figure 2B (ii).   
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Since angiogenesis is crucial for tumor development, CD31 has been widely used 
as a marker to highlight the density of intratumoral vessels and the degree of 
neoangiogenesis. Based on CD31 staining, the number of vasculature structures was 
significantly more in the pre-treatment tumor section as compared to post–treatment 
section Figure 2A & B (iii).   VEGF is considered to be another important, directly acting 
and potent angiogenic agent over-expressed in tumors. The results reveal a higher 
expression of cytoplasmic localization of VEGF in the pre-treatment tumor section 
(Figure 2A iv). The expression was reduced in the CRLX101 post-treatment tumor 
section (Figure 2B iv). Figure 2 A &B (v) show the H & E staining in pre- and post- 
tumors sections.  
 We next compared the IHC expression scores of Topo- 1, Ki-67, CaIX, CD31 
and VEGF in pre-treatment biopsy tumor sections in representative patients enrolled in 
the study. The expression level of all proteins was higher in tumor from the patient 
surviving 3 months as compared to tissue from a patient who survived 27 months (Figure 
3A (i-v). Figure 3A (vi) show the H & E staining in tumor sections from both patients. 
Although, the average staining intensity score for Topo-1, Ki-67, CaIX and CD31 was 
also higher in group 1 as compared to group 2 (Figure 3B, i-v), it was significantly 
(p<0.05)  different for only Topo-1 and Ki-67 expression. The expression of all the 
proteins was inversely proportional to survival duration of the patients (Figure 3C, i-v). 
The expression score for Ki-67 was best correlated (p<0.01), followed by Topo-1 and 
CaIX being next (p=0.01) respectively. The expression of CD31 and VEGF correlated the 
least with the survival time (p<0.05 and p=0.27). The expression score for Ki-67 when 
combined with another variable such as either of CaIX, CD31 or Topo-1 resulted in a 
significant increase in the correlation coefficient (p<0.01) respectively with survival time. 
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These data suggest that the combined score of two variables may be used for predicting 
the outcome of the treatment.  
 
Plasma Cytokine and Platelet Levels 
Elevated plasma cytokine levels have been reported in different types of cancers 
and sometimes correlated with increased side effects of the treatment and disease 
progression.  There is a burgeoning amount of evidence, particularly in breast and 
prostate cancer, that markers of increased immune inflammatory activity are associated 
with fatigue.
24 Although the clinical meanings of the relationships is not yet known, the 
increase in levels of cytokines likely contributes to the symptoms of asthenia, fatigue and 
lethargy, as supported by cytokine-induced sickness behavior in animal models and 
humans.
25,26
  The most common CRLX101 related adverse effect in patients included 
fatigue, anemia, neutropenia, leucopenia and thrombocytopenia.  To better understand 
causes of fatigue, we assessed plasma cytokine levels (listed in Figure 4) prior to 
treatment and on day 8 of cycle 1 of CRLX101 treatment. Majority of these cytokines 
were already at levels several fold higher than the normal range in all the patients and 
mean plasma levels of most of these cytokines increased further although not significant, 
with CRLX101 treatment. The survival duration was longer for patients with lower IL 
levels as compared to the patients with shorter survival duration (Table S2).  Our results 
showed that IL2R, the receptor for IL-2 levels expression was almost 2X higher for group 
1 than group 2 (715±138 vs 350±50pg/ml, p<0.05). This is in agreement with a report 
showing  a significantly higher IL2R expression in late stage lung cancer as compared to 
early stage colorectal cancer.
27
 Similarly, expression for IL-8 was several folds higher for 
the group 1 compared to group 2 (164±96 vs 30±5pg/ml). Although not significant, this 
level increased further after CRLX101 treatment in group 1 while decreasing in group 2. 
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These results are supported by a study an in vivo tumorigenesis analysis in pancreatic 
cancer showing that tumor tissues from patients with higher serum IL-8 levels grew faster 
than those with lower IL-8 levels.
28
 The levels of MIP-1a and MCP-1 were higher in the 
longer surviving group and increased further after CRLX101 treatment.  IFN- also 
increased after CRLX-101 treatment. Additionally, while not statistically significant, only 
IL-1Ra, IL-10 and IL-12p40/p70 values were reduced after CRLX101 treatment. In 
patients having an adverse event (AE) grade of ≥ 3, higher percentage change in plasma 
cytokine levels were observed when compared to a patient with an AE of grade 1 (Figure 
4A). Among all patients with AE of grade 3, only one patient was from the longer 
survival group. Our results are in agreement with previous reports shown in patients with 
breast and prostate cancer.
24,29
 Other studies have also shown that high innate production 
capacity of proinflammatory cytokines is associated with increased tumor burden, 
aggressiveness and metastasis.
30,31
 
Additionally, analysis of patient blood samples revealed that mean platelet counts 
were transiently decreased, on day 14 of cycle 1 compared with pre-treatment levels. This 
decrease was significant only in group 1 patients whose survival duration was shorter 
than 6 months (p = .034, Figure 4B). Platelet aggregation was also observed in some 
cases; however, neither the platelet number nor aggregation of platelets was associated 
with clotting or excessive bleeding in any patient.  A significant decrease in hemoglobin 
in group 1 compared to group 2 (15% vs 3.5%) may also account for fatigue (p= 0.05, 
Figure 4C). Portenoy and Itri demonstrated an association between chemotherapy- 
induced mild-to-moderate anemia and both fatigue and quality-of-life impairment. They 
also showed that  patients with an increase in hematocrit of >6% also demonstrated 
significant improvement in energy level and daily activities.
32
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Response and genotyping analysis   
To exclude the possibility that the lower toxicity observed in these patients might 
be due to allele frequency difference in SNPs of drug metabolism genes, we compared 
the allele frequencies between the patient cohort in the current study (n=8, Group 1 and 
n=7, Group 2) and the global population data obtained from Affymetrix, which included 
713 HapMap samples consisting of individuals from various descent. Figure 5A indicates 
that the frequencies of the alleles on DMET array in these patients are very similar to 
those of the population (Chi Square test p > 0.05). The enzyme activity of genes on the 
DMET array was also categorized with Affymetrix’s Genotyping Console, and the 
association of these enzymes with toxicity and response phenotype was examined. Using 
Fisher’s exact test (P<0.01), 157 SNPs were identified as having different allele 
frequency in patients compared to the general population. However, none of these SNPs 
were found to be associated with either toxicity phenotype or response status. The only 
SNP found to be overlapping with response association was a non-synonymous SNP in 
flavin containing mono-oxygenase 2 (FMO2) (Figure 5B). Although the sample size is 
small, these results suggest the observed lower toxicity in these patients was not likely 
due to different genotypes in these DMET SNPs. These results indicate that the lower 
toxicity in the current patient cohort is not due to allele frequency difference in drug 
metabolism genes. 
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Discussion 
Numerous preclinical and clinical studies have demonstrated that treatment with 
Topo-1 inhibitors result in tumor regression.
6,11,33,34
 It has also been suggested that the 
cytotoxic effects of these inhibitors are dependent on the stabilization of topoisomerase-
DNA complex.
35
 Both in vitro and in vivo studies have demonstrated that sensitivity to 
these agents is modulated by absolute value of Topo-1 levels and Topo-1 protein 
expression is correlated well with poor patient survival.  Our results showed a significant 
decrease in the expression of Topo-1 in post treatment sections. This is in agreement with 
other studies showing a decrease in expression and activity of Topo-1 after treatment 
with camptothecin or its analogs.
16,35
  Our results also showed significantly decreased 
expression of Topo-1 in patients with longer survival duration as compared to the group 
with shorter survival duration.  These results are not supported by the earlier hypothesis 
that lower expression of Topo-1 is correlated with a worse response to Topo-1 
inhibitors.
36,37
  However, results of other studies from Dutch colorectal cancer group 
failed to replicate the findings and concluded that although absolute Topo-1 expression 
may play a role, it is likely that additional pathways contribute to irinotecan sensitivity of 
Topo-1.
38,39
 Therefore, these results indicate that clinical significance of Topo-1 is still 
unknown and remains controversial as prognostic marker. 
Our results showed a decrease in expression of Ki-67 post-CRLX101 treatment. 
Also, the expression of Ki-67 was higher in the tumor section of a patient who survived 
for 3 months as compared to the one with a longer survival time (27 months). Our results 
are in agreement with studies that suggested a positive correlation between Ki-67 score 
and shorter survival.
40,41
 We have previously shown that CRLX101 treatment inhibited 
expression of CaIX in a tumor sections. Also the expression of CaIX was lower in the 
sample from the patient with longer survival duration as compared to the other. However, 
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mRNA expression of HIF-1 showed insignificant difference before and after treatment 
(data not shown). These results are consistent with earlier reports of inhibition of hypoxia 
by camptothecin analogs.
11,42,43
  HIF-1α is known to upregulate genes involved in a 
variety of processes such as angiogenesis.
17
  VEGF and CD31 have been examined 
widely as biomarkers for angiogenesis and are shown to correlate with stage, grade, and 
prognosis of patients.
21,22
 Our results showed a decrease in expression of VEGF and 
CD31 (microvessel density) in the post-treatment tissue sample.  Also, the tissue from the 
patient with a shorter duration of survival had stronger expression of both the proteins as 
compared to the tissue from the longer surviving patient.  Therefore, we conclude that 
expression of Ki-67, CaIX, CD31 and VEGF are inversely proportional to patient’s 
survival duration. These results are consistent with previous reports that increased 
proliferation, positive expression of HIF-1 and VEGF are associated with shorter 
disease-free survival and overall survival in patients with gastric cancer.
40,44
 
High incidence of gastrointestinal toxicity, hemorrhagic cystisis and severe bone 
marrow suppression in early clinical trials dampened the usage of CPT and encouraged 
the development of  CPT analogs .
45
  Two less potent small molecule derivatives 
(topotecan and irinotecan) achieved notable improvement over CPT but are still not well 
tolerated.
46
  Our phase 1/2a result showed CRLX101- related adverse events including 
fatigue, cystitis, anemia, neutropenia, leucopenia and thrombocytopenia in some patients, 
but these events have been far less in severity as compared to CPT or its derivatives.
16
 
The levels of most common interleukins increased after treatment with CRLX101; 
however, they were lower in the group whose survival time was longer than 6 months 
suggesting that secretion of cytokines might be used as a tool to monitor the therapeutic 
indices of the drug.  Also, higher levels of MIP-1a in the longer surviving group and its 
increase after treatment with CRLX101 in both groups is in agreement with the report 
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that tumor cells transfected with the MIP-1a gene might be useful as an effective therapy 
for the treatment of certain tumors.
47
  Low serum MCP-1 levels have been identified in 
patients with worse prognosis similar to that reported in the current study. Interferon has 
been shown to facilitate anti-tumor activity by promoting antigen presenting cell 
mediated expansion of cytotoxic T cells and activating macrophages to release molecules 
such as superoxide.
48
 Our results also show an increase in IFN- levels after CRLX-101 
treatment. A phase Ib study of the hepatocyte growth factor (HGF)-inhibitor AMG-102 in 
combination with either bevacizumab or motesanib identified post-treatment elevation in 
HGF levels which coincided with a 75% increase in all grades of fatigue, similar to those 
reported in the current study.
49
 This data suggests that high innate production capacity of 
proinflammatory cytokines is associated with shorter survival, probably because of 
increased tumor growth and metastasis. A significant decrease in platelet counts and 
hemoglobin by day 14 of the first treatment cycle may provide a possible mechanism for 
treatment-related fatigue; however, additional studies are needed to clarify the 
relationship.  
The DMET array enables a cost-effective measurement of existing and new 
metabolic pathway involvement by providing broad coverage of relevant 
pharmacogenetic markers in one assay. However, due to the small sample size, the chi- 
square p value was not significant for the patient group and a larger cohort should be used 
to validate these results.  
In summary, these results reinforce the statement of the importance of CRLX101 
as a promoter of increased anti-tumor activity in patients with solid tumor malignancies. 
These results also confirm that the possible mechanistic rationale for treatment with 
CRLX101 in the patients is inhibition of proliferation, hypoxia and angiogenesis 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
19 
 
correlating with slow tumor growth presumably due to lack of survival factors supplied 
through blood and therefore longer survival time.  
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Figure Legends 
Figure 1. Effect of CRLX101 treatment on Topoisomerase expression: (A), 
Representative panel of immunohistochemical staining of Topo-1 in tumor sections 
extracted from a patient before and after treatment with CRLX101 (magnification 40x). 
(B), The Kaplan-Meier analysis for overall survival on day 8 of CRLX101 treatment 
stratified by Topo-1 expression (from blood samples).  (C) and (D), Comparison of 
mRNA levels of Topo-1 determined by RT-PCR before and after CRLX101 treatment. 
Each sample was measured three times.  The two groups were divided based on time of 
survival from date of CRLX101 administration. 
Figure 2.  Representative panel of immunohistochemical analysis of   Ki-67, carbonic 
anhydrase (CaIX), cluster of differentiation molecule (CD31 also known as PECAM-1) 
and vascular endothelial growth factor (VEGF) in tumors extracted from a patient before 
(A) and after treatment (B) with CRLX101 (Same tumor tissue used for as in Figure 1A, 
Magnification 40x).  The staining for all the proteins was strong for pretreatment section 
as compared to post treatment section; (i) The expression level of Ki-67 in nucleus of 
tumor cells; (ii) A membranous expression of CaIX in pretreatment, (iii) Expression of 
CD31 (cell junctions) and (iv) Cytoplasmic expression of VEGF (v) H&E staining of 
corresponding sections from untreated and treated tumors. 
Figure 3.  Representative panel of immunohistochemical analysis (A) Topo-1, Ki-67, 
carbonic anhydrase (CaIX), CD31 and vascular endothelial growth factor (VEGF) in 
tumors extracted from patients surviving 3 months and 27 months from the date of 
administration of CRLX101 (Magnification 40x).  The staining for all the proteins (i) 
Topo-1, (ii) Ki-67, (iii) CaIX, (iv) CD31 and (v) VEGF were stronger for patient tumor 
section surviving 3 months as compared to patient surviving 27 months. (iv) H&E 
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staining of corresponding tumor sections from two patients. (B i-v)  Histograms showing 
the difference in expression of Topo-1, Ki-67, CaIX, CD31 and VEGF (scoring based on 
IHC staining intensity) in two groups (n=4 each) divided based on survival duration 
(p≤0.05, represents a significant difference).  (C i-v) Relationship between expression of 
proteins and survival duration from the time CRLX101 was administered in the patients 
with available biopsy sample. 
Figure 4.  Cytokine, platelet and hemoglobin analyses 8 days after treatment with 
CRLX101. (A) Comparison of percent change in plasma cytokine levels after CRLX101 
treatment measured (in duplicate)  by Thirty-Plex Antibody Bead Kit and calculated 
using Bio-Plex Manager 5.0 software with a 5-parameter curve-fitting algorithm applied 
for standard curve.  The two groups were divided based on occurrence of adverse events 
of grade 3 and 1 in patients after treatment with CRLX101. (B) Platelet counts in blood 
samples from pretreatment and 15 day post CRLX101 treatment in two groups divided 
based on survival duration. Significant (p<0.05) decrease in platelet count observed in 
patients with shorter duration. (C)  Hemoglobin levels in blood samples from 
pretreatment and 15day post CRLX101 treatment in two groups divided based on 
survival duration from time of drug administration. Significant (p<0.05) decrease in 
hemoglobin observed in patients with shorter duration.  
Figure 5. Allele frequency analysis by DMET array: (A) Comparison of Allele 
Frequency in the Patients vs. the Population. Allele frequency in global populations was 
obtained from Affymetrix’s annotation file (59 CEU, 90 CHB, 87 CHD, 91 JPT, 89 
LWK, 60 MEX, and 119 YRI). (B) SNPs showing different allele frequency from 
Population associated with Response or Toxicity. 
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Graphical Abstract 
 
The clinical efficacy of CRLX101, the nanoparticulate conjugate of cyclodextrin 
based polymer molecule and camptothecin is evaluated in patients with 
treatment refractory solid tumor malignancies by immunohistochemistry and 
pharmacogenomics. The decrease in expression of topoisomerase-1, Ki-67, 
CaIX, VEGF and CD31 after treatment with CRLX101 indicate inhibition of 
proliferation, hypoxia and angiogenesis correlating with slow tumor growth.   
 
